18889881171
Kalkine 0
countryflagUS

Autolus Therapeutics Ltd

Healthcare US AUTL

2.325USD
0.07(2.88%)

Last update at 2025-07-08T16:45:00Z

Day Range

2.232.35
LowHigh

52 Week Range

2.017.45
LowHigh

Fundamentals

  • Previous Close 2.26
  • Market Cap1069.46M
  • Volume540417
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-172.59774M
  • Revenue TTM10.50M
  • Revenue Per Share TTM0.06
  • Gross Profit TTM -130.86000M
  • Diluted EPS TTM-1.24

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-12-31
Income before tax -173.20500M -165.98800M -166.25700M -139.00800M -23.25300M
Minority interest - - - - -
Net income -148.83900M -142.09600M -142.09400M -123.84900M -20.64800M
Selling general administrative 31.90M 31.86M 34.97M 39.45M 7.59M
Selling and marketing expenses - - - - -
Gross profit 6.19M 2.33M 0.24M 2.91M -45.41500M
Reconciled depreciation 7.42M 8.46M 5.66M 4.61M -
Ebit -163.78500M -164.20700M -168.14500M -137.86000M -72.42600M
Ebitda -156.36300M -155.74900M -162.48700M -133.24900M -
Depreciation and amortization 7.42M 8.46M 5.66M 4.61M -
Non operating income net other - - - - -
Operating income -163.78500M -164.20700M -168.14500M -137.86000M -25.01000M
Other operating expenses 173.72M 166.65M 168.39M 144.87M -
Interest expense 8.90M 1.10M 1.89M 1.15M 0.00000M
Tax provision -24.36600M -23.89200M -24.16300M -15.15900M -2.60500M
Interest income 1.71M 0.26M 0.54M 2.54M 0.66M
Net interest income -7.19700M -0.84300M 0.54M 2.54M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -24.36600M -23.89200M -24.16300M -15.15900M -8.48800M
Total revenue 6.19M 2.33M 0.24M 2.91M 0.30M
Total operating expenses 173.72M 166.65M 168.39M 144.87M 73.90M
Cost of revenue - - - 105.42M 46.89M
Total other income expense net -9.42000M -1.78100M 1.89M -1.14800M 6.06M
Discontinued operations - - - - -
Net income from continuing ops -148.83900M -142.09600M -142.09400M -123.84900M -57.87500M
Net income applicable to common shares -148.83900M -142.09600M -142.09400M -123.84900M -57.87500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 375.38M 490.27M 405.56M 294.24M 303.53M
Intangible assets - - 0.07M 0.16M 0.25M
Earning assets - - - - -
Other current assets 35.74M 0.20M 0.24M 43.69M 0.28M
Total liab 263.91M 191.60M 92.24M 84.20M 48.69M
Total stockholder equity 111.47M 298.67M 313.32M 210.03M 254.84M
Deferred long term liab - - - - -
Other current liab 44.74M 40.80M 0.15M 0.50M 0.72M
Common stock 0.00800M 0.00800M 0.00400M 0.00300M 0.00200M
Capital stock 0.00800M 0.00800M 0.00400M 0.00300M 0.00200M
Retained earnings -878.56200M -670.17900M -521.34000M -379.24400M -237.15000M
Other liab - 126.02M 47.14M - -
Good will - - - - -
Other assets 0.00000M 6.08M 6.23M 7.41M 2.45M
Cash 239.57M 382.44M 310.34M 153.30M 210.64M
Cash and equivalents - - - - -
Total current liabilities 44.74M 46.37M 28.55M 33.63M 24.98M
Current deferred revenue -5.15600M - 23.52M 27.29M 20.68M
Net debt -186.59900M -358.18000M -289.34000M -99.13800M -184.42200M
Short term debt 5.05M 5.04M 4.45M 3.59M 2.51M
Short long term debt - - - - -
Short long term debt total 52.97M 24.26M 21.00M 54.16M 26.22M
Other stockholder equity 1019.02M 1007.74M 843.23M 595.13M 500.68M
Property plant equipment - 58.42M 52.32M 89.68M 51.57M
Total current assets 275.30M 425.77M 346.95M 196.98M 249.26M
Long term investments - - - - -
Net tangible assets - 298.67M 313.25M 209.87M 254.59M
Short term investments - - - - -
Net receivables 24.54M 28.98M 26.25M 29.68M 30.52M
Long term debt - - - - -
Inventory -24.54200M 14.16M 10.12M -29.68500M 7.81M
Accounts payable 0.10M 0.53M 0.43M 2.26M 1.07M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -28.99200M -38.89800M -8.57000M -5.86100M -8.69100M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00300M 0.00200M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.36M 4.01M 4.40M 5.66M 2.04M
Deferred long term asset charges - - - - -
Non current assets total 100.08M 64.50M 58.61M 97.25M 54.28M
Capital lease obligations 52.97M 24.26M 21.00M 54.16M 26.22M
Long term debt total - - - - -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30 2018-12-31
Investments -10.84100M -8.85700M -14.68100M -18.66800M -
Change to liabilities 0.02M -1.81600M 1.44M -1.45100M 1.30M
Total cashflows from investing activities -10.84100M -8.85700M -14.68100M -18.66800M -13.18900M
Net borrowings - - - - -
Total cash from financing activities 223.61M 284.06M 74.42M 108.86M 156.49M
Change to operating activities 3.95M 5.95M -0.02900M -14.75300M 2.36M
Net income -148.83900M -142.09600M -142.09400M -123.84900M -20.64800M
Change in cash 72.08M 156.59M -57.34500M -6.12500M -29.53400M
Begin period cash flow 310.68M 154.09M 211.43M 217.56M 247.09M
End period cash flow 382.76M 310.68M 154.09M 211.43M 217.56M
Total cash from operating activities -112.30800M -117.86100M -117.75800M -101.48400M -42.52500M
Issuance of capital stock 163.85M 245.90M 74.42M 108.86M -
Depreciation 7.42M 8.46M 5.66M 4.61M 0.65M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - 108.86M -
Other cashflows from financing activities 59.76M 38.16M 74.42M 108.86M -
Change to netincome 25.14M 11.64M 17.27M 33.96M 9.70M
Capital expenditures 10.84M 8.86M 14.68M 18.67M 4.42M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3.97M 4.14M 1.41M -16.20400M -
Stock based compensation 12.01M 9.94M 20.11M 30.21M -
Other non cash items 13.39M 1.77M -1.49500M 4.14M -
Free cash flow -123.14900M -126.71800M -132.43900M -120.15200M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AUTL
Autolus Therapeutics Ltd		 0.07 2.88% 2.33 - - 786.19 11.97 676.30 -7.3251
NVO
Novo Nordisk A/S		 -0.5201 0.75% 68.80 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 70.12 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 10.38 2.26% 469.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 18.29 3.40% 556.40 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics Ltd

The Mediaworks, London, United Kingdom, W12 7FP

Key Executives

Name Title Year Born
Dr. Christian Martin Itin Ph.D. CEO & Director 1964
Dr. Martin Pule M.D., MBBS Founder, Sr. VP & Chief Scientific Officer 1972
Mr. Christopher Vann Sr. VP & COO 1965
Mr. David Brochu Sr. VP & Chief Technical Officer 1956
Mr. Andrew J. Oakley ACA, BEcon, MBA Sr. Advisor 1962
Mr. Brent Rice Sr. VP, Chief Commercial Officer & Site Head of US 1966
Dr. Edgar E. W. Braendle M.D., Ph.D. Sr. VP & Chief Devel. Officer 1960
Dr. Lucinda Crabtree Ph.D. Chief Financial Officer NA
Ms. Olivia Manser Director of Investor Relations NA
Dr. Chris Williams Sr. VP of Corp. Devel. 1980

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.